Changes in Biosimilar Knowledge among European Crohn’s Colitis Organization [ECCO] Members: An Updated Survey-Reference-Cited by-同舟云学术

Changes in Biosimilar Knowledge among European Crohn’s Colitis Organization [ECCO] Members: An Updated Survey

Published:2016-04-25 Issue:11 Volume:10 Page:1362-1365
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:ECCOJC

Author:

Danese Silvio,Fiorino Gionata,Michetti Pierre

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Link

http://academic.oup.com/ecco-jcc/article-pdf/10/11/1362/13746280/jjw090.pdf

Reference13 articles.

1. European Medicines Agency. Inflectra. 2013. Available on http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002778/human_med_001677.jsp&mid=WC0b01ac058001d124, Accessed September 29, 2013.

2. European Medicines Agency. Remsima. 2013. Available on http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002576/human_med_001682.jsp&mid=WC0b01ac058001d124, Accessed September 29, 2013.

3. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

4. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey Study;BioDrugs;2024-01-12

2. Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease;Therapeutic Advances in Gastroenterology;2024-01

3. Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe;Advances in Therapy;2023-11-14

4. Rare variant burden analysis from exomes of three consanguineous families reveals LILRB1 and PRSS3 as potential key proteins in inflammatory bowel disease pathogenesis;Frontiers in Medicine;2023-05-05

5. Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia;Expert Opinion on Biological Therapy;2023-04-19